Revisiting the role of alkylating agents in multiple myeloma: Up-to-date evidence and future perspectives-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Revisiting the role of alkylating agents in multiple myeloma: Up-to-date evidence and future perspectives

Published:2023-07 Issue: Volume:187 Page:104040
ISSN:1040-8428
Container-title:Critical Reviews in Oncology/Hematology
language:en
Short-container-title:Critical Reviews in Oncology/Hematology

Author:

Costa Bruno Almeida,Mouhieddine Tarek H.,Ortiz Ricardo J.,Richter Joshua^ORCID

Publisher

Elsevier BV

Subject

Oncology,Hematology

Reference257 articles.

1. Current status of autologous stem cell transplantation for multiple myeloma;Al Hamed;Blood Cancer J.,2019

2. Treatment for multiple myeloma. Combination chemotherapy with different melphalan dose regimens;Alexanian;JAMA,1969

3. KD-PACE salvage therapy for aggressive relapsed refractory multiple myeloma, plasma cell leukemia and extramedullary myeloma;Alsouqi;Clin. Lymphoma Myeloma Leuk.,2021

4. A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Français du Myélome;Attal;New Engl. J. Med.,1996

5. Single versus double autologous stem-cell transplantation for multiple myeloma;Attal;New Engl. J. Med.,2003

Cited by 8 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Dual-targeted NAMPT inhibitors as a progressive strategy for cancer therapy;Bioorganic Chemistry;2024-08

2. Multiple myeloma: signaling pathways and targeted therapy;Molecular Biomedicine;2024-07-04

3. Comparable efficacy of oral bendamustine versus intravenous administration in treating hematologic malignancies;Cancer Chemotherapy and Pharmacology;2024-06-15

4. Novel chemotherapy combination of carfilzomib with dexamethasone, cyclophosphamide, etoposide and cisplatin (K-DCEP) for the treatment of relapsed/refractory aggressive plasma cell dyscrasias;Leukemia & Lymphoma;2024-06-02

5. Metronomic chemotherapy in hematology: Lessons from preclinical and clinical studies to build a solid rationale for future schedules;Cancer Letters;2024-06

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3